Clophide 200 Injection contains Cyclophosphamide 200mg, a widely used alkylating chemotherapeutic agent trusted across oncology centers and cancer-care hospitals. It plays a critical role in the treatment of several malignancies including breast cancer, lymphomas, multiple myeloma, leukemia, and ovarian cancer. Its reliability, strong clinical relevance, and broad therapeutic utility make it an essential component in oncology medicine portfolios.
Cyclophosphamide works by interfering with DNA replication and suppressing abnormal cancer cell growth, helping enhance the effectiveness of multi-drug chemotherapy protocols. Its immunosuppressive properties also make it valuable in certain autoimmune conditions when administered under strict medical guidance. Clophide 200 Injection offers precise strength for controlled dosing in IPD and oncology infusion settings.
For distributors and oncology channel partners, Clophide 200 Injection is a high-demand cancer-care product, regularly procured by multispecialty hospitals, oncology departments, government institutes, day-care centers, and private cancer clinics. Its established prescription demand ensures stable movement and repeat orders throughout the year.
Adding Clophide 200 to your portfolio strengthens your oncology and chemotherapy segment, opening opportunities in hospital supply chains, institutional tenders, export consignments, pharmacy oncology shelves, and third-party manufacturing. Its strong therapeutic relevance and essential role in cancer treatment make it a high-value, essential addition for pharmaceutical distributors.